|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute on Drug Abuse (NIDA) |
|---|---|
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00142779 |
Purpose
Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Fluoxetine, a medication that is currently used to treat depression and anxiety disorders, may also be effective at diminishing cocaine use in individuals with severe cocaine addiction. This study will evaluate the effectiveness of fluoxetine at reducing cocaine use in individuals addicted to cocaine and opioids who are concurrently receiving methadone treatment.
| Condition | Intervention |
|---|---|
|
Cocaine-Related Disorders Opioid-Related Disorders |
Drug: Fluoxetine |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Serotonin Treatment of Cocaine Dependence |
| Estimated Enrollment: | 220 |
| Study Start Date: | April 2001 |
| Study Completion Date: | March 2006 |
| Primary Completion Date: | January 2006 (Final data collection date for primary outcome measure) |
Individuals addicted to cocaine often experience feelings of restlessness, irritability, anxiety, and paranoia. Reducing cocaine use can lead to depression. In an attempt to alleviate the depressive symptoms, individuals may resume drug use. Fluoxetine, a medication that is currently used to treat depression and panic attacks, may assist at reducing cocaine use in individuals addicted to cocaine. By increasing serotonin, a chemical in the brain that helps maintain mental balance, fluoxetine may lessen depressive symptoms and decrease the reinforcing effects of cocaine. Voucher incentive programs, in which items or services are offered as a reward for remaining drug-free, are also a useful component of substance abuse treatment. Preliminary research has shown that fluoxetine, when combined with an incentive program, is an effective treatment for reducing cocaine use. Further research is needed to confirm the benefits of fluoxetine for cocaine and opioid addicts. The purpose of this study is to evaluate the effectiveness of fluoxetine, in combination with a voucher incentive program, at reducing cocaine use in methadone-maintained cocaine and opioid addicts.
This 33-week study will enroll individuals addicted to both cocaine and opioids who are concurrently enrolled in a methadone treatment program. Participants will be randomly assigned to receive either 60 mg of fluoxetine or placebo on a daily basis for 12 weeks from Weeks 8 through 19. Study visits will occur once a week. Questionnaires and self-reports will be completed to assess medication side effects and cocaine use. Cocaine levels will be monitored three times a week with urine tests. During the 12 weeks of treatment, participants will also be randomly assigned to either take part in a voucher incentives program or not take part in the program. Participants in the voucher program will receive a voucher that may be exchanged for various items and services for each urine test with a negative cocaine result.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Maryland | |
| Johns Hopkins University School of Medicine | |
| Baltimore, Maryland, United States, 21224 | |
| Principal Investigator: | Eric C. Strain, MD | Johns Hopkins University |
More Information
| Responsible Party: | Johns Hopkins University School of Medicine ( Eric C. Strain ) |
| Study ID Numbers: | NIDA-10754-2, R01-10754-2, DPMC |
| Study First Received: | September 1, 2005 |
| Last Updated: | May 15, 2009 |
| ClinicalTrials.gov Identifier: | NCT00142779 History of Changes |
| Health Authority: | United States: Federal Government |
|
Cocaine Addiction Cocaine Dependence Opiate Addiction Opiate Dependence |
|
Dopamine Uptake Inhibitors Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Disorders of Environmental Origin Anesthetics Opioid-Related Disorders Pathologic Processes Mental Disorders Sensory System Agents Therapeutic Uses Vasoconstrictor Agents Substance-Related Disorders |
Antidepressive Agents, Second-Generation Cocaine Antidepressive Agents Cocaine-Related Disorders Disease Central Nervous System Depressants Cardiovascular Agents Serotonin Uptake Inhibitors Pharmacologic Actions Anesthetics, Local Fluoxetine Serotonin Agents Dopamine Agents Peripheral Nervous System Agents Central Nervous System Agents |